Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03223428 · ClinicalTrials.gov registry record
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
A clinical trial of Carcinoid Syndrome, sponsored by TerSera Therapeutics.
- Completed
- Registry status
- 223
- Enrollment target
- 1
- Study location
NCT03223428 is a study of Carcinoid Syndrome that has completed, run by TerSera Therapeutics. The registered enrollment target is 223 participants, above the 88-participant average among 4 other Carcinoid Syndrome trials with a reported enrollment target (153% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03223428, a study of Carcinoid Syndrome, has completed, sponsored by TerSera Therapeutics.
- COMPLETED
- Registry status
- 223 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to estimate the proportion of carcinoid syndrome (CS) patients who are satisfied with their overall symptom control, 6 months after initiating treatment with telotristat ethyl (XERMELO).
Conditions Studied
Interventions
- DRUG Xermelo
Study Locations (1)
North Carolina
- RTI-HS - Research Triangle Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2017-06-22 |
| Est. Completion | 2022-01-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03223428
The ClinicalTrials.gov registry entry for NCT03223428 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 88-participant average among 4 other Carcinoid Syndrome trials with a reported enrollment target (153% higher). The listed sponsor is TerSera Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoid Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Xermelo is the first listed.
NCT03223428 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03223428 about?
NCT03223428 is a clinical study titled "Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO". The primary objective of the study is to estimate the proportion of carcinoid syndrome (CS) patients who are satisfied with their overall symptom control, 6 months after initiating treatment with telotristat ethyl (XERMELO).
What is the current status of trial NCT03223428?
This trial is currently completed. The enrollment target is 223 participants. The study started on 2017-06-22. Estimated completion is 2022-01-14.
What conditions does trial NCT03223428 study?
This clinical trial studies the following conditions: Carcinoid Syndrome.
What interventions are being tested in trial NCT03223428?
The interventions under investigation include: Xermelo (DRUG).
Who is sponsoring clinical trial NCT03223428?
This trial is sponsored by TerSera Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03223428 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoid Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
RECRUITING · Phase 3
-
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
COMPLETED · Phase 2
-
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.